FDA-Drug2026-09-09Class IIPROCESSING DEFECT

Baxter Nexterone amiodarone injection recalled for CGMP manufacturing deviations

OTHERNationwide distributionDrugs

What this means

Baxter Healthcare has recalled multiple lots of Nexterone (amiodarone HCI) injection due to deviations from good manufacturing practices (CGMP) during production. The affected lots were distributed nationwide, Puerto Rico, and Chile. No injuries have been reported.

  • Check your facility's inventory against the affected lot numbers and expiration dates listed in the recall notice.
  • Do not use affected lots; quarantine and return them to your supplier or Baxter Healthcare.
  • Contact Baxter Healthcare or your distributor for replacement stock if needed.
The agency's original wording
Hazard

CGMP Deviations

Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide; Puerto Rico; and Chile.
Affected count
N/A
Manufactured in
1 Baxter Pkwy, N/A, Deerfield, IL, United States
Products
Nexterone (amiodarone HCI), 360 mg/200 mL (1.8 mg/mL) in GALAXY Single-Dose Container, sterile, Nonpyrogenic, iso-osmotic solution in Dextrose, Baxter Healthcare Corporation, Deerfield, IL 60015, Made in the USA, NDC 43066-360-20.

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0814-2026

More Baxter recalls

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Free · One email a week · Unsubscribe anytime